PE20071163A1 - Dispositivo de liberacion transdermica de meptazinol - Google Patents

Dispositivo de liberacion transdermica de meptazinol

Info

Publication number
PE20071163A1
PE20071163A1 PE2006001676A PE2006001676A PE20071163A1 PE 20071163 A1 PE20071163 A1 PE 20071163A1 PE 2006001676 A PE2006001676 A PE 2006001676A PE 2006001676 A PE2006001676 A PE 2006001676A PE 20071163 A1 PE20071163 A1 PE 20071163A1
Authority
PE
Peru
Prior art keywords
meptazinol
salt
transdermal
layer
release
Prior art date
Application number
PE2006001676A
Other languages
English (en)
Inventor
Richard Franklin
Original Assignee
Shire Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Shire Pharmaceuticals Inc filed Critical Shire Pharmaceuticals Inc
Publication of PE20071163A1 publication Critical patent/PE20071163A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
    • A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38—Cellulose; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/06—Ointments; Bases therefor; Other semi-solid forms, e.g. creams, sticks, gels
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
    • A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
    • A61K9/703—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms characterised by shape or structure; Details concerning release liner or backing; Refillable patches; User-activated patches
    • A61K9/7084—Transdermal patches having a drug layer or reservoir, and one or more separate drug-free skin-adhesive layers, e.g. between drug reservoir and skin, or surrounding the drug reservoir; Liquid-filled reservoir patches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Dermatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Inorganic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Neurosurgery (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)

Abstract

SE REFIERE A UN DISPOSITIVO TRANSDERMICO PARA LA LIBERACION TRANSDERMICA DE UNA SAL DE MEPTAZINOL, QUE COMPRENDE: i) UNA CAPA DE RESPALDO; ii) UNA CAPA DE DEPOSITO; iii) UNA CAPA DE MEMBRANA DE CONTROL O MEMBRANA MICROPOROSA NO CONTROLADORA; iv) UNA CINTA ADHESIVA, LA CUAL ES OPCIONALMENTE COMO UN ANILLO PERIMETRICO O COMO UNA MATRIZ GEOMETRICA O COMBINACION; v) UN REVESTIMIENTO DE LIBERACION. EN DONDE LA CAPA DE DEPOSITO CONTIENE UNA COMPOSICION QUE COMPRENDE: a) UNA FORMA DE SAL DE MEPTAZINOL O SAL DE PRECURSOR DE MEPTAZINOL, SIENDO PREFERIDA LA SAL DE CLORHIDRATO O TRIFLUORACETATO, EN UNA CANTIDAD QUE RESULTA EN LA LIBERACION DE UNA CANTIDAD EFECTIVA DEL COMPUESTO CUANDO SE AGREGA AL DISPOSITIVO PARA LUEGO SER APLICADO EN LA PIEL; Y b) UN PORTADOR. ESTA DISPOSITIVO AUMENTA LA BIODISPONIBILIDAD DE MEPTAZINOL Y PROPORCIONA ALIVIO ANALGESICO LOCALIZADO O SISTEMICO
PE2006001676A 2005-12-21 2006-12-21 Dispositivo de liberacion transdermica de meptazinol PE20071163A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US75335705P 2005-12-21 2005-12-21
US86211406P 2006-10-19 2006-10-19

Publications (1)

Publication Number Publication Date
PE20071163A1 true PE20071163A1 (es) 2007-11-30

Family

ID=38198475

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2006001676A PE20071163A1 (es) 2005-12-21 2006-12-21 Dispositivo de liberacion transdermica de meptazinol

Country Status (15)

Country Link
US (1) US20070224253A1 (es)
EP (1) EP1962817B1 (es)
AR (1) AR058598A1 (es)
AT (1) ATE488229T1 (es)
AU (1) AU2006331596A1 (es)
CA (1) CA2633369A1 (es)
DE (1) DE602006018355D1 (es)
DK (1) DK1962817T3 (es)
EA (1) EA200801575A1 (es)
MX (1) MX2008008050A (es)
PE (1) PE20071163A1 (es)
PT (1) PT1962817E (es)
TW (1) TW200800223A (es)
UY (1) UY30056A1 (es)
WO (1) WO2007075883A2 (es)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090280064A1 (en) * 2005-06-24 2009-11-12 Rao Papineni Transdermal delivery of optical, spect, multimodal, drug or biological cargo laden nanoparticle(s) in small animals or humans
US10208158B2 (en) 2006-07-10 2019-02-19 Medipacs, Inc. Super elastic epoxy hydrogel
EP2227635A2 (en) 2007-12-03 2010-09-15 Medipacs, Inc. Fluid metering device
US20090186832A1 (en) * 2008-01-18 2009-07-23 Shire Llc Amino acid peptide pro-drugs of phenolic analgesics and uses thereof
CN105902482A (zh) * 2008-06-25 2016-08-31 Fe3医学有限公司 用于经皮递送治疗有效量的铁的贴片和方法
US9008765B2 (en) 2009-02-12 2015-04-14 Incube Labs, Llc System and method for biphasic transdermal iontophoretic delivery of therapeutic agents for the control of addictive cravings
US8190252B2 (en) 2009-02-12 2012-05-29 Incube Labs, Llc Iontophoretic system for transdermal delivery of active agents for therapeutic and medicinal purposes
US8961492B2 (en) 2009-02-12 2015-02-24 Incube Labs, Llc System and method for controlling the iontophoretic delivery of therapeutic agents based on user inhalation
WO2010093472A2 (en) * 2009-02-12 2010-08-19 Incube Labs, Llc Method and apparatus for oscillatory iontophoretic transdermal delivery of a therapeutic agent
US8821945B2 (en) 2009-04-25 2014-09-02 Fe3 Medical, Inc. Method for transdermal iontophoretic delivery of chelated agents
US8423131B2 (en) * 2009-06-26 2013-04-16 Incube Labs, Llc Corrosion resistant electrodes for iontophoretic transdermal delivery devices and methods of use
US8903485B2 (en) 2009-08-06 2014-12-02 Incube Labs, Llc Patch and patch assembly for iontophoretic transdermal delivery of active agents for therapeutic and medicinal purposes
US9238102B2 (en) 2009-09-10 2016-01-19 Medipacs, Inc. Low profile actuator and improved method of caregiver controlled administration of therapeutics
US8685038B2 (en) 2009-12-07 2014-04-01 Incube Labs, Llc Iontophoretic apparatus and method for marking of the skin
US9500186B2 (en) 2010-02-01 2016-11-22 Medipacs, Inc. High surface area polymer actuator with gas mitigating components
WO2011094814A1 (en) 2010-02-05 2011-08-11 Phosphagenics Limited Carrier comprising non-neutralised tocopheryl phosphate
US8986279B2 (en) 2010-02-10 2015-03-24 Incube Labs, Llc Methods and architecture for power optimization of iontophoretic transdermal drug delivery
SG184181A1 (en) 2010-03-30 2012-10-30 Phosphagenics Ltd Transdermal delivery patch
WO2012061556A1 (en) 2010-11-03 2012-05-10 Flugen, Inc. Wearable drug delivery device having spring drive and sliding actuation mechanism
EP2685992A4 (en) 2011-03-15 2014-09-10 Phosphagenics Ltd AMINO-QUINOLINES AS KINASE INHIBITORS
JP6133843B2 (ja) 2011-03-24 2017-05-31 インキューブ ラブズ，リミテッド ライアビリティー カンパニーＩｎＣｕｂｅ Ｌａｂｓ，ＬＬＣ 治療剤の二相性経皮イオン泳動送達用のシステム及び方法
US8636696B2 (en) 2011-06-10 2014-01-28 Kimberly-Clark Worldwide, Inc. Transdermal device containing microneedles
JP2015510956A (ja) 2012-03-14 2015-04-13 メディパックス インコーポレイテッド 過剰反応性分子を含むスマートポリマー材料
WO2014132239A1 (en) 2013-02-28 2014-09-04 Kimberly-Clark Worldwide, Inc. Drug delivery device
BR112015020328B1 (pt) 2013-02-28 2022-05-31 Sorrento Therapeutics, Inc Dispositivo de aplicação transdérmica de droga
US10376308B2 (en) 2015-02-05 2019-08-13 Axon Therapies, Inc. Devices and methods for treatment of heart failure by splanchnic nerve ablation
EP3383371B1 (en) 2015-12-09 2024-05-01 Avecho Biotechnology Limited Pharmaceutical formulation
JP7217230B2 (ja) 2016-07-29 2023-02-02 アクソン セラピーズ，インク． 内臓神経アブレーションによる心不全の治療の為のデバイス、システム及び方法
CN110662733A (zh) 2016-12-21 2020-01-07 埃维科生物技术有限公司 方法
WO2019118976A1 (en) 2017-12-17 2019-06-20 Axon Therapies, Inc. Methods and devices for endovascular ablation of a splanchnic nerve
WO2019148094A1 (en) 2018-01-26 2019-08-01 Axon Therapies, Inc. Methods and devices for endovascular ablation of a splanchnic nerve
AU2020296866A1 (en) 2019-06-20 2021-10-14 Axon Therapies, Inc. Methods and devices for endovascular ablation of a splanchnic nerve
AU2021208701A1 (en) 2020-01-17 2022-07-07 Axon Therapies, Inc. Methods and devices for endovascular ablation of a splanchnic nerve
CN113491675B (zh) * 2021-07-01 2023-05-23 北京航空航天大学 一种预防瘢痕的微针创口贴及其制备方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1539277A (en) * 1977-09-16 1979-01-31 Wyeth John & Brother Ltd Hexahydro-1h-azepines
IE55189B1 (en) * 1982-07-08 1990-06-20 Wyeth John & Brother Ltd Pharmaceutical compositions
IE60941B1 (en) * 1986-07-10 1994-09-07 Elan Transdermal Ltd Transdermal drug delivery device
US6916486B2 (en) * 1996-02-19 2005-07-12 Acrux Dds Pty Ltd Transdermal delivery of analgesics
PT1094781E (pt) * 1998-07-07 2008-10-08 Transdermal Technologies Inc Composições para administração transdérmica rápida e não irritante de agentes farmacologicamente activos e métodos para formulação de tais composições e sua administração
US6716449B2 (en) * 2000-02-08 2004-04-06 Euro-Celtique S.A. Controlled-release compositions containing opioid agonist and antagonist
DE10059415A1 (de) * 2000-11-30 2002-06-06 Gruenenthal Gmbh Verwendung von schwachen Opioiden und gemischten Opioidagonisten/-antagonisten zur Therapie der Harninkontinenz
DK1530469T3 (da) * 2002-08-20 2009-05-04 Euro Celtique Sa Transdermal dosisform omfattende et aktivt middel og et salt og fri baseform af en antagonist
KR101159828B1 (ko) * 2003-04-30 2012-07-04 퍼듀 퍼머 엘피 활성제 구성요소 및 활성제 층의 원위부에 억제제 구성요소를 포함하는 내변조성 경피제형

Also Published As

Publication number Publication date
EP1962817A2 (en) 2008-09-03
EP1962817B1 (en) 2010-11-17
WO2007075883A2 (en) 2007-07-05
US20070224253A1 (en) 2007-09-27
DE602006018355D1 (de) 2010-12-30
WO2007075883A9 (en) 2007-08-23
CA2633369A1 (en) 2007-07-05
UY30056A1 (es) 2007-06-29
ATE488229T1 (de) 2010-12-15
MX2008008050A (es) 2009-04-06
PT1962817E (pt) 2010-12-13
AU2006331596A1 (en) 2007-07-05
AR058598A1 (es) 2008-02-13
WO2007075883A3 (en) 2008-01-17
EA200801575A1 (ru) 2008-12-30
DK1962817T3 (da) 2011-03-07
TW200800223A (en) 2008-01-01

Similar Documents

Publication Publication Date Title
PE20071163A1 (es) Dispositivo de liberacion transdermica de meptazinol
ES2581574T3 (es) Sistema terapéutico transdérmico para la administración del principio activo buprenorfina
PT2529732T (pt) Sistema terapeutico transdérmico com uma camada adesiva, um processo para siliconizar uma camada de suporte do sistema e utilização da camada de suporte
WO2008133982A3 (en) Adhesive patch with aversive agent
MX337361B (es) Sistema de entrega de medicamento transdermico que comprende una capa de liberacion recubierta.
ES2422605T3 (es) Anticuerpo contra klotho-beta para utilizar en el tratamiento de tumores, cáncer o trastornos proliferativos celulares
ECSP11010824A (es) Tratamiento para diabetes en pacientes inapropiados para terapia con metformina.
BR0313091A (pt) Sistema de liberação transdérmica aperfeiçoado para a administração de rotigotina
AR073563A1 (es) Terapia de combinacion para el tratamiento de diabetes y estados relacionados
GT200600046A (es) Terapia de combinacion
MX366560B (es) Parche adhesivo con composicion antimicrobiana.
CL2011000186A1 (es) Metodos para eliminar o prevenir el crecimiento de un microbio en un sustrato mediante la aplicacion de compuestos derivados de tetrakis (n-alquilpiridinio)- porfirina; composicion topica que comprende dicho compuesto; y metodo para prevenir y tratar una infeccion de la piel en un sujeto.
BR112012008775B8 (pt) curativo adesivo
RU2016109449A (ru) Устройства для трансдермальной доставки дексмедетомидина и способы их применения
PE20151147A1 (es) Sistema de liberacion transdermica
WO2007035942A3 (en) Transdermal risperidone delivery system
MY183873A (en) Transdermal therapeutic system for application of an agent
MX2012002727A (es) Sistema terapeutico transdermico para administrar fentanilo o un analogo del mismo.
ES2646737T3 (es) Sistema terapéutico transdérmico para clorhidrato de ácido 5-aminolevulínico
NZ595549A (en) Transdermal therapeutic system containing nicotine
MX2009008993A (es) Dispositivo para la administracion percutanea de bisoprolol.
DE502007003630D1 (de) Transdermales therapeutisches system mit ionenpaar-mikroreservoiren
AR089765A1 (es) Un sistema para el suministro de un farmaco
NZ584190A (en) Once-a-day replacement transdermal administration of fentanyl
BR0313092A (pt) Sistema de liberação transdérmica aperfeiçoado

Legal Events

Date Code Title Description
FD Application declared void or lapsed